Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > A transcript from the Questions Dan answered at Bloom Burton

<< Previous

Bullboard Posts

Next >>

Comment by Pronorvistaon May 05, 2022 12:49pm

177 Views

Post# 34659080

RE:RE:A transcript from the Questions Dan answered at Bloom Burton

Depth by Price for T : ATE at 2022-05-05 12:43:43

	Bid					Ask
Price Volume Orders	0.66 7,000 2	0.68 2,710 2	0.69 1,500 2	0.70 501,750 3	0.71 500 1	0.72 4,500 2	0.74 5,000 2	0.75 500 1	0.77 1,500 1	0.78 4,000 1